SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year
In a SARS-CoV-2 seroprevalence study conducted with 1,655 working adults in spring of 2020, 12 of the subjects presented with positive neutralization test (NT) titers (>1:10). They were here followed up for 1 year to assess their Ab persistence. We report that 7/12 individuals (58%) had NT_50...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.822316/full |
| _version_ | 1819278697632366592 |
|---|---|
| author | Erika Garner-Spitzer Angelika Wagner Michael Kundi Hannes Stockinger Anna Ohradanova-Repic Laura Gebetsberger Anna-Margarita Schoetta Venugopal Gudipati Johannes B. Huppa Renate Kunert Patrick Mayrhofer Thomas R. Kreil Maria R. Farcet Eva Hoeltl Ursula Wiedermann |
| author_facet | Erika Garner-Spitzer Angelika Wagner Michael Kundi Hannes Stockinger Anna Ohradanova-Repic Laura Gebetsberger Anna-Margarita Schoetta Venugopal Gudipati Johannes B. Huppa Renate Kunert Patrick Mayrhofer Thomas R. Kreil Maria R. Farcet Eva Hoeltl Ursula Wiedermann |
| author_sort | Erika Garner-Spitzer |
| collection | DOAJ |
| description | In a SARS-CoV-2 seroprevalence study conducted with 1,655 working adults in spring of 2020, 12 of the subjects presented with positive neutralization test (NT) titers (>1:10). They were here followed up for 1 year to assess their Ab persistence. We report that 7/12 individuals (58%) had NT_50 titers ≥1:50 and S1-specific IgG ≥50 BAU/ml 1 year after mild COVID-19 infection. S1-specific IgG were retained until a year when these levels were at least >60 BAU/ml at 3 months post-infection. For both the initial fast and subsequent slow decline phase of Abs, we observed a significant correlation between NT_50 titers and S1-specific IgG and thus propose S1-IgG of 60 BAU/ml 3 months post-infection as a potential threshold to predict neutralizing Ab persistence for 1 year. NT_50 titers and S1-specific IgG also correlated with circulating S1-specific memory B-cells. SARS-CoV-2-specific Ab levels after primary mRNA vaccination in healthy controls were higher (Geometric Mean Concentration [GMC] 3158 BAU/ml [CI 2592 to 3848]) than after mild COVID-19 infection (GMC 82 BAU/ml [CI 48 to 139]), but showed a stronger fold-decline within 5–6 months (0.20–fold, to GMC 619 BAU/ml [CI 479 to 801] vs. 0.56–fold, to GMC 46 BAU/ml [CI 26 to 82]). Of particular interest, the decline of both infection- and vaccine-induced Abs correlated with body mass index. Our data contribute to describe decline and persistence of SARS-CoV-2-specific Abs after infection and vaccination, yet the relevance of the maintained Ab levels for protection against infection and/or disease depends on the so far undefined correlate of protection. |
| first_indexed | 2024-12-24T00:16:08Z |
| format | Article |
| id | doaj.art-b4ff2729839b47aca362fe1b6114797c |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-24T00:16:08Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-b4ff2729839b47aca362fe1b6114797c2022-12-21T17:24:44ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-02-01910.3389/fmed.2022.822316822316SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 YearErika Garner-Spitzer0Angelika Wagner1Michael Kundi2Hannes Stockinger3Anna Ohradanova-Repic4Laura Gebetsberger5Anna-Margarita Schoetta6Venugopal Gudipati7Johannes B. Huppa8Renate Kunert9Patrick Mayrhofer10Thomas R. Kreil11Maria R. Farcet12Eva Hoeltl13Ursula Wiedermann14Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaInstitute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaCenter for Public Health, Medical University of Vienna, Vienna, AustriaInstitute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaInstitute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaInstitute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaInstitute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaInstitute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaInstitute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaDepartment of Biotechnology, University of Natural Resources and Life Sciences, Vienna, AustriaDepartment of Biotechnology, University of Natural Resources and Life Sciences, Vienna, AustriaGlobal Pathogen Safety, Baxter AG, a Takeda company, Vienna, AustriaGlobal Pathogen Safety, Baxter AG, a Takeda company, Vienna, AustriaHealth Center Erste Bank, Erste Bank, Vienna, AustriaInstitute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaIn a SARS-CoV-2 seroprevalence study conducted with 1,655 working adults in spring of 2020, 12 of the subjects presented with positive neutralization test (NT) titers (>1:10). They were here followed up for 1 year to assess their Ab persistence. We report that 7/12 individuals (58%) had NT_50 titers ≥1:50 and S1-specific IgG ≥50 BAU/ml 1 year after mild COVID-19 infection. S1-specific IgG were retained until a year when these levels were at least >60 BAU/ml at 3 months post-infection. For both the initial fast and subsequent slow decline phase of Abs, we observed a significant correlation between NT_50 titers and S1-specific IgG and thus propose S1-IgG of 60 BAU/ml 3 months post-infection as a potential threshold to predict neutralizing Ab persistence for 1 year. NT_50 titers and S1-specific IgG also correlated with circulating S1-specific memory B-cells. SARS-CoV-2-specific Ab levels after primary mRNA vaccination in healthy controls were higher (Geometric Mean Concentration [GMC] 3158 BAU/ml [CI 2592 to 3848]) than after mild COVID-19 infection (GMC 82 BAU/ml [CI 48 to 139]), but showed a stronger fold-decline within 5–6 months (0.20–fold, to GMC 619 BAU/ml [CI 479 to 801] vs. 0.56–fold, to GMC 46 BAU/ml [CI 26 to 82]). Of particular interest, the decline of both infection- and vaccine-induced Abs correlated with body mass index. Our data contribute to describe decline and persistence of SARS-CoV-2-specific Abs after infection and vaccination, yet the relevance of the maintained Ab levels for protection against infection and/or disease depends on the so far undefined correlate of protection.https://www.frontiersin.org/articles/10.3389/fmed.2022.822316/fullSARS-CoV-2infectionneutralizing Absantibody kineticsvaccinationpersistence |
| spellingShingle | Erika Garner-Spitzer Angelika Wagner Michael Kundi Hannes Stockinger Anna Ohradanova-Repic Laura Gebetsberger Anna-Margarita Schoetta Venugopal Gudipati Johannes B. Huppa Renate Kunert Patrick Mayrhofer Thomas R. Kreil Maria R. Farcet Eva Hoeltl Ursula Wiedermann SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year Frontiers in Medicine SARS-CoV-2 infection neutralizing Abs antibody kinetics vaccination persistence |
| title | SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year |
| title_full | SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year |
| title_fullStr | SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year |
| title_full_unstemmed | SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year |
| title_short | SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year |
| title_sort | sars cov 2 specific antibody ab levels and the kinetic of ab decline determine ab persistence over 1 year |
| topic | SARS-CoV-2 infection neutralizing Abs antibody kinetics vaccination persistence |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.822316/full |
| work_keys_str_mv | AT erikagarnerspitzer sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT angelikawagner sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT michaelkundi sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT hannesstockinger sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT annaohradanovarepic sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT lauragebetsberger sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT annamargaritaschoetta sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT venugopalgudipati sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT johannesbhuppa sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT renatekunert sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT patrickmayrhofer sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT thomasrkreil sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT mariarfarcet sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT evahoeltl sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year AT ursulawiedermann sarscov2specificantibodyablevelsandthekineticofabdeclinedetermineabpersistenceover1year |